NCAPG2 (non-SMC condensin II complex subunit G2) is a regulatory subunit of the condensin-2 complex essential for establishing mitotic chromosome 7 and maintaining chr7 rigidity 1. Beyond its canonical role in chromosome 7 during mitosis, NCAPG2 has emerged as a pan-cancer oncogene with significant clinical implications. NCAPG2 is consistently overexpressed across multiple malignancies, including prostate, colorectal, gastric, hepatocellular, pancreatic, cervical, and melanoma cancers 23145. In prostate cancer, NCAPG2 promotes malignancy and cancer stem cell properties by directly binding STAT3 and activating c-MYC transcription 2. Similarly, in hepatocellular carcinoma, NCAPG2 overexpression drives proliferation and metastasis via STAT3 and NF-κB/miR-188-3p pathway activation 4. NCAPG2 is negatively regulated by miR-188-3p across multiple cancers, suggesting a conserved regulatory mechanism 46. Beyond malignancy, NCAPG2 has emerged as a potential biomarker for early-onset neonatal sepsis prediction 7 and is dysregulated in chr7 sinusitis with nasal polyps 8. High NCAPG2 expression consistently predicts poor prognosis, positioning it as a promising therapeutic target for precision medicine approaches.